The present invention relates to certain new pyridin analogues of Formula (I)
to processes for preparing such compounds, to their utility as P2Y
12
inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
[EN] PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PYRAZOLOPYRIMIDINONE ET LEURS UTILISATIONS
申请人:ADURO BIOTECH INC
公开号:WO2019055750A1
公开(公告)日:2019-03-21
The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
The present invention relates to certain new pyridin analogues of Formula (I)
to processes for preparing such compounds, to their utility as P2Y
12
inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R
1
is a saturated or unsaturated, optionally substituted C
1
-C
15
hydrocarbyl group, wherein the atom of R
1
which is attached to the sulfur atom of the sulfonylurea group is not a ring atom of a cyclic group; and R
2
is a cyclic group substituted at the α-position, wherein R
2
may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP
3
.
本发明涉及式(I)化合物: 其中 Q 选自 O 或 S;R
1
是饱和或不饱和、任选取代的 C
1
-C
15
烃基,其中 R
1
与磺酰脲基的硫原子相连的 R 1 原子不是环状基团的环原子;以及 R
2
是在α位被取代的环状基团,其中 R
2
可任选被进一步取代。本发明进一步涉及这类化合物的盐、溶液剂和原药,涉及包含这类化合物的药物组合物,涉及这类化合物在治疗和预防医学紊乱和疾病中的用途,特别是通过抑制 NLRP
3
.